Attorney Docket No.: 053665-5010-02

REMARKS

Claims 1-107 are currently pending in the application. Claims 1-54 have been canceled. Claims 104-107 have been added. Claims 56 and 58 have been amended to correct a spelling error.

Applicants have amended the Specification herein to claim benefit to a cross-referenced application, change the title, correct spelling errors, and correspond with the new claims. Applicants have also amended the specification to delete subject matter that is not necessary to support the claims. Substitute drawings are being submitted herewith to correspond to the deleted text in the specification.

No new matter has been added.

In view of the foregoing remarks, it is respectfully requested that all independent claims are allowable. As such, it is respectfully requested that all dependent claims are allowable because such claims depend from an allowable base claim. A Notice of Allowance is earnestly solicited.

EXCEPT for issue fees p ayable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application, including fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time, fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

Dated: Aller So 2003

Kim R. Jessum

Reg. No. 43,694

Correspondence Address:

MORGAN, LEWIS & BOCKIUS LLP

1701 Market Street

Philadelphia, Pa 19103-2921

(215) 963-5000

AMENDMENTS TO THE DRAWINGS

Please substitute Figures 1-7 in place of Figures 1-9.

Attachment: Replacement sheets 1-7.

FIGURE 1A

FIGURE 1C






FIGURE 1B



Substituted malonic acid chlorides (CICOCHRCOCI) could also be used in the above reaction; $R = CH_3$, CH_2CH_3 , C_6H_5

Synthesis of AZT-Phosphocholine Conjugate



lipid & ara-C coupled through phosphate ester

FIGURE 5A

lipid & gemcitabine coupled through phosphate ester

BEST AVAILABLE COPY

FIGURE 5B

lipid & ara-C coupled through phosphonate ester

FIGURE 6A

lipid & gemcitabine coupled through phosphonate ester

lipid coupled to methotrexate through an ester